Year: 2025
Type: article
Abstract: Rifaximin is a minimally absorbed oral antibiotic, primarily targeting ammonia-producing gut bacteria, and is commonly used alongside lactulose to prevent recurrent hepatic encephalopathy (HE) in cirrhosis.1 Its favorable safety profile supports its use, including in patients with transjugular intrahepatic porto-systemic shunts, and it is under study for conditions like spontaneous bacterial peritonitis and refractory ascites. Hence, up to 30% of hospitalized patients with cirrhosis and infections receive rifaximin.
Source: JHEP Reports
Authors: Florent Artru, Virginia Hernández-Gea
Institutions: Inserm, Centre Hospitalier Universitaire de Rennes, Nutrition, métabolismes et cancer, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,110
OpenAlex ID: W4409055346